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Abstract
Purpose Sensitivity to a tyrosine kinase inhibitor (TKI) is
correlated with the presence of somatic mutations that
affect the kinase domain of epidermal growth factor
receptor (EGFR). Development of resistance to TKI is a
major therapeutic problem in non-small cell lung cancer
(NSCLC). Aim of this study is to identify agents that can
overcome TKI resistance in NSCLC.
Methods We used a carefully selected panel of 12
NSCLC cell lines to address this clinical problem. Initially,
the cell lines were treated with a variety of 10 compounds.
Cellular proliferation was measured via MTT assay. We
then focused on the gefitinib-resistant, EGFR mutant cell
lines [H1650: exon 19 and PTEN mutations; and H1975:
exons 20 (T790M) and 21 (L858R)] to identify agents that
could overcome TKI resistance.
Results Both 17-DMAG (Hsp90 inhibitor) and belinostat
(histone deacetylase inhibitor, HDACi) effectively decreased
the growth of almost all NSCLC lines. Also, belinostat
markedly decreased the expression of EGFR and phospho-
Akt in the cells. Combination of 17-DMAG and belinostat
synergistically inhibited in vitro proliferation of these cells.
Furthermore, both agents and their combination almost
completely prevented TKI-resistant tumor formation (EGFR
T790M mutation) in a xenograft model.
Conclusion These results suggest that the combination of
17-DMAG and belinostat should be examined in a clinical
trial for TKI-resistant NSCLC cell.
Keywords Non-small cell lung cancer (NSCLC) 
Tyrosine kinase inhibitor (TKI)  EGFR  17-DMAG 
Belinostat  Combination chemotherapy
Introduction
Lung cancer is the leading cause of cancer-related deaths,
accounting for one-third of worldwide deaths from cancer.
Non-small cell lung cancer (NSCLC) represents 80 % of
lung cancers [1, 2]. The epidermal growth factor (EGFR) is
an important therapeutic target in NSCLC [3]. Gefitinib
was the first small-molecule EGFR tyrosine kinase inhib-
itor (TKI) that received FDA approval in 2003 [4]. Initial
clinical studies found that only a minority of individuals
with NSCLC responded to either gefitinib or erlotinib [5].
Asian non-smoking females were noted to be particularly
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sensitive to this class of drugs [4, 6]. Soon, investigators
discovered that sensitivity to these TKIs was correlated
with somatic mutations of the kinase domain of EGFR,
such as either deletions within exon 19 or a L858R muta-
tion in exon 21 [3, 7–9]. Individuals with these tumors
often responded to TKI therapy, but usually had progres-
sive disease after 6–12 months of therapy. These resistant
tumors often acquired either an additional mutation
(T790M) in exon 20 of EGFR or a second mutation in the
downstream pathway of EGFR, both resulting in the
development of resistance to EGFR-TKI [10–12].
A major therapeutic priority is to discover drugs
and/or drug combinations that can inhibit proliferation of
NSCLCs after they have developed an EGFR mutation that
renders these cells TKI-resistant. After examining 10 dif-
ferent potential therapeutic compounds, we focused on two
of the most active: 17-DMAG (Hsp90 inhibitor) and beli-
nostat (HDACi). The Hsp90 chaperone complex is neces-
sary for stability and activity of client proteins required for
cellular homeostasis [13], and inhibition of Hsp90 results
in proteasome degradation of its client proteins [14].
HDACi acetylates both histones and thousands of nonhis-
tone cellular proteins confounding our understanding of
how they mediate their anticancer affect. 17-DMAG and
belinostat have different modes of action and toxicities. We
found that both compounds potently suppressed prolifera-
tion of NSCLC cells, and when combined, they markedly
inhibited these cells both in vitro and in vivo. Our data
show that this drug combination overcomes TKI resistance
in NSCLC cells.
Materials and methods
Reagents and NSCLC cell lines
The following compounds were used in this study:
LY-333531 [ALEXIS Biochemicals (CA, USA)]; cisplatin
[APP Pharmaceuticals, LLC (IL, USA)]; panobinostat
[Selleck Chemicals (TX, USA)]; gefitinib; paclitaxel,
docetaxel, gemcitabine and dasatinib [LC Laboratories
(MA, USA)]; and 17-DMAG and belinostat [provided by
National Cancer Institute (USA)]. All reagents were dis-
solved in dimethyl sulfoxide (DMSO), and the final con-
centration of DMSO never exceeded 0.1 % in culture.
Antibodies, Akt (pan), phospho-Akt (Ser473), p70S6K,
phospho-p70S6K (Thr421/Ser424), EGF receptor, phos-
pho-EGF receptor (Tyr1068) and GAPDH were purchased
from Cell Signaling (MA, USA).
The human NSCLC cell lines: H1299, H1666, H460,
H520, PC9, HCC827, H1650 and H1975 were purchased
from the American Type Culture Collection (Manassas,
VA). HCC2279, HCC2935, HCC4006 and H820 were
kindly provided by Dr. Roman K. Thomas (Max Planck
Institute for Neurological Research). All cell lines were
cultured in RPMI1640 supplemented with 10 % fetal calf
serum, 100 U/ml of penicillin, and 100 lg/ml of strepto-
mycin. The H1975 and H820 cell lines had EGFR T790M
mutations in exon 20, associated with gefitinib and erloti-
nib resistance.
Cell proliferation assays
NSCLC cells were seeded at a density of 4,000–15,000 per
well in 96-well plates. After 24 h, cells were cultured with
multiple concentrations of drugs for 72 h. Cell proliferation
was determined by using CellTiter 96 Non-Radioactive
Cell Proliferation Assay (Promega) according to the man-
ufacturer’s instructions, and the plates were read by a
fluorescence spectrometer. Half-maximal inhibitory con-
centrations (‘‘IC50-values’’) were determined from the
images under the growth inhibition curves using Prism 4.0
software.
Western blot analysis
Cells were harvested, washed with PBS, and lysed in
ProteoJET Mammalian Cell Lysis Regent (Fermentas)
supplemented with ProteoBlock Protease Inhibitor Cocktail
(Fermentas). Protein concentrations were measured by
Bradford assay (Bio-Rad, Richmond, CA). Equal amounts
of protein were dissolved in sodium dodecyl sulfate–
polyacrylamide gel electrophoresis sample loading buffer
and electrophoresed in a polyacrylamide gel (7.5 or 10 %).
After electrophoresis, the proteins were electrotransferred
to a polyvinylidene difluoride membrane (Immobilon,
Millipore, Bedford, MA). Immunoblotting was performed
using each antibody and detected by ECL-Plus reagent
(Amersham, Boston, MA).
In vivo experiments
Murine experiments were done in accord with a protocol
reviewed and approved by the Institutional Animal Care
and Usage Committee at the University of Singapore, in
compliance with the Guide for the Care and Use of Lab-
oratory Animals. The TKI-resistant (EGFR exons 20 and
21 mutations) H1975 cells (1 9 107 cells) in the presence
of matrigel (BD Biosciences) were injected into the flanks
of nude mice (Biological Resource Center Singapore) (day
1). Each treatment group consisted of two tumors on the
flanks of seven to eight mice. Doses of drugs (day 2–day
30) were as follows: belinostat (50 mg/kg); 17-DMAG
(15 mg/kg); and combination therapy (belinostat 50 mg/kg
and 17-DMAG 15 mg/kg). After day 30, dose of drugs was
decreased: belinostat (25 mg/kg); 17-DMAG (7.5 mg/kg);
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and combination therapy (belinostat 25 mg/kg and 17-
DMAG 7.5 mg/kg). The drugs were given intraperitoneally
(i.p.) every other day. Control mice received i.p. injections
with the diluent L-arginine (100 mg/kg) in water. Every
tumor was measured with a caliper every other day, and the
volume was calculated using the formula: (long diame-
ter) 9 (short diameter)2/2. At the end of experiments,
blood chemistries were measured (ALP, CRE, GLU,
PHOS, CA, BUN, AST, ALT, TBIL, TP, AMYL, ALB,
Na, K, Cl and LDL). The mice were anesthetized, and their
tumors were carefully dissected, weighted, and divided into
half. Half was used for immunochemistry, and the other
was used for real-time RT-PCR and Western blotting.
Immunohistochemistry
Paraffin-embedded tumor sections (4 lm) were placed on
glass slides. This was followed by deparaffinization,
rehydration, blocking of endogenous peroxidase activity
and heat-induced antigen retrieval. The slides were stained
with murine monoclonal Ki67 [clone MIB1(dilution 1:
100), DakoCytomation (CA, USA)]. The signal was
detected using the MACH 2 Mouse HRP Polymer [Biocare
Medical (CA, USA)]. All sections were visualized with
the diaminobenzidine reaction and counterstained with
hematoxylin.
Statistical analysis
Data were collected using a minimum of three experiments
and used to calculate the mean ± SD. Statistical signifi-
cance was calculated using ANOVA or Bonferroni/Dunn
multiple comparison test was considered significant at
p values \0.05.
Results
Growth inhibition of gefitinib-resistant NSCLC
A panel of NSCLC cell lines were selected to encompass
three groups: cohort #1, no mutation of EGFR (H1666,
H460, H1299 and H520); cohort #2, EGFR mutation of
either exon 19 or 21, and an additional TKI resistance-
inducing mutation (H1650, H1975 and H820); and cohort
#3, EGFR mutation of exon 19 and sensitive to TKI
inhibitors (PC9, HCC827, HCC2279, HCC2935 and
HCC4006) [Table 1]. The cellular proliferation of this
panel of 12 NSCLC cell lines was examined by MTT over
72 h in the presence of increasing concentrations of a
variety of compounds (gefitinib, dasatinib, panobinostat,
belinostat, 17-DMAG LY-333531, cisplatin, gemcitabine,
paclitaxel and docetaxel). Dose–response curves were
generated, and the concentration that caused 50 % growth
inhibition (IC50) was calculated (Table 1). Almost all cell
lines were highly sensitive (IC50 range 0.037–0.29 lM) to
dasatinib (src inhibitor) except the EGFR ‘‘wild-type’’
cell lines H1666 and H460 (IC50 range [10 lM). All
NSCLC cell lines were highly sensitive (IC50 range
0.0006–0.14 lM) to panobinostat (HDACi), and almost all
NSCLC cell lines were sensitive (IC50 range 0.29–1.2 lM)
to belinostat (HDACi) except the EGFR-normal H1666 cell
line (IC50 range [10 lM). 17-DMAG (Hsp90 inhibitor)
(IC50 range 0.0005–0.095 lM) and paclitaxel and doce-
taxel (mitotic inhibitors) (IC50 range 0.0014–0.029 lM)
had prominent antiproliferative activity. LY-333531
(PKCb inhibitor) required a high concentration (IC50 range
4.7 to [10 lM) to inhibit cell growth. H1650 and H820
cells (EGFR mutant, TKI-resistant) were more resis-
tant (IC50 0.65, 1.2 lM, respectively) to gemcitabine
Table 1 Inhibition of proliferation of NSCLC cells were seeded in 96-well plates
Inhibition of proliferation of NSCLC cells [IC50 (lM)]
EGFR wild-type EGFR mutant, TKI-resistant EGFR mutant, TKI-sensitive
H1666 H460 H1299 H520 H1975 H1650 H820 PC9 HCC2279 HCC827 HCC2935 HCC4006
Gefitinib [10 [10 [10 [10 8.2 [10 4.5 0.002 0.008 0.004 0.04 0.23
Dasatinib [10 [10 0.07 0.27 0.12 0.18 0.29 0.11 0.037 0.06 0.17 0.4
Panobinostat 0.12 0.05 0.04 0.016 0.03 0.04 0.005 0.016 0.015 0.009 0.029 0.06
Belinostat [10 0.86 1.2 0.75 0.68 0.88 0.4 0.29 0.4 0.29 0.97 0.46
17-DMAG 0.06 0.005 0.04 0.06 0.02 0.008 0.02 0.005 0.095 0.03 0.0005 0.003
LY-333531 [10 [10 [10 [10 [10 [10 [10 [10 4.7 6.2 4.7 7.9
Cisplatin 3.2 8 5.7 3 4.6 1.6 2.3 5 [10 5.2 [10 5.1
Gemcitabine 0.4 0.35 0.2 0.17 0.097 0.65 1.2 0.36 0.096 0.33 0.074 0.071
Paclitaxel 0.013 0.004 0.03 0.02 0.004 0.004 0.012 0.029 0.016 0.007 0.006 0.004
Docetaxel 0.004 0.003 0.008 0.004 0.002 0.004 0.005 0.006 0.005 0.003 0.0014 0.003
After 24 h, cells were cultured with multiple concentrations of drugs for 72 h. Cell proliferation was determined by using CellTiter 96 non-
radioactive cell proliferation assay. Half-maximal inhibitory concentrations (‘‘IC50-values’’ lM) were determined
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(nucleoside analog) than the EGFR ‘‘wild-type’’ cell lines
(IC50 range 0.17–0.4 lM). Antiproliferative activity of
cisplatin (platinum-based chemotherapy) was also corre-
lated with their EGFR gene mutational status (p = 0.0486)
(EGFR mutant, TKI-sensitive [ EGFR wild-type [ EGFR
mutant, TKI-resistant) (Supplement Fig. 1).
Inhibition of EGFR expression
A representative NSCLC cell line of each group [‘‘wild-
type’’ (H460 cells), TKI-resistant (exon 19 and PTEN
mutant, H1650 cells) and TKI-sensitive (exon 19 mutant,
PC9 cells)] was selected for further study. Mutant EGFR is
a major driver of cell proliferation. 17-DMAG, belinostat,
panobinostat and docetaxel decreased the levels of EGFR
in cells from all three NSCLC groups (Fig. 1a). 17-DMAG,
belinostat and panobinostat also decreased the levels of
EGFR in H1975 cells (EGFR exons 20 and 21 mutations
and TKI-resistant) (Supplement Fig. 2A). Dasatinib did not
decrease expression of EGFR in the cells with either wild-
type EGFR or exon 19 mutant, PC9 (Fig. 1a).
Inhibition of activated Akt (p-Akt) downstream
of EGFR
Activated Akt (p-Akt) is one of the important molecules in
the activated EGFR signaling pathway. 17-DMAG atten-
uated the expression of p-Akt in all three subgroups of cell
lines (Fig. 1b). Belinostat decreased levels of p-Akt in the
TKI-resistant [H1650 and H1975 (Supplement Fig. 2B)]
and TKI-sensitive (PC9) EGFR mutant cell lines. In con-
trast, expression of total Akt either decreased only mod-
estly or even increased in the three subtypes of NSCLC
after exposure to each of the compounds (Fig. 1b). We also
examined the ability of these two agents to inhibit p-Akt
after serum starvation and short exposure (4 h) to EGF
(Fig. 2). This model system tests the ability of the com-
pound to inhibit a major growth stimulation pathway after
PC9 -exon 19 mutation
H1650 -exon19 and PTEN mutations
H460 -EGFR wild-typea
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GAPDH
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Fig. 1 17-DMAG and belinostat decreased EGFR expression in all
subtypes of NSCLC. a H460 (TKI-resistant, EGFR wild-type), H1650
(TKI-resistant, EGFR exon 19 and PTEN mutations) and PC9 (TKI-
sensitive, EGFR exon 19 mutation) cells were treated for 24 h with
either dasatinib (200 nM), 17-DMAG (50 nM), belinostat (500 nM),
panobinostat (50 nM) or docetaxel (10 nM). Lysates were Western
blotted and probed with antibody against EGFR and GAPDH (loading
control). b 17-DMAG and belinostat decrease H460, H1650 and PC9
cells, which were treated for 24 h with 17-DMAG (50 nM) and
belinostat (500 nM), Western blotted and probed with antibody
against p-Akt (Ser473), pan-Akt and GAPDH (loading control)
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exposure to activating ligand. Belinostat decreased p-Akt
in H460 (EGFR wild-type) and PC9 (TKI-sensitive), but
not in H1650 cells (TKI-resistant); however, starting levels
of p-Akt in these cells were extremely low after EGF
stimulation alone (Fig. 2a). 17-DMAG did not modulate
levels of p-Akt in H460 (EGFR wild-type), but did
decrease expression in the PC9 cells (TKI-sensitive) and
the H1650 cells (TKI-resistant) (Fig. 2b).
Combination of 17-DMAG and belinostat markedly
inhibits cell proliferation of NSCLC in vitro
The above data suggested that both 17-DMAG and beli-
nostat can inhibit growth of gefitinib-resistant NSCLC
cells. Therefore, we examined whether the combination of
17-DMAG and belinostat versus either alone had an
enhanced antiproliferative activity in H1650 cells. Co-
treatment with 17-DMAG (5, 10 or 20 nM) and belinostat
(100, 250 or 500 nM) inhibited growth of H1650 NSCLC
cells (EGFR exon 19 and PTEN mutations), greater than
either inhibitor alone, with 10 nM of 17-DMAG and either
250 or 500 nM of belinostat showing synergistic antipro-
liferative activity (Fig. 3a, columns 12 and 15, Fig. 3b).
Likewise, the combination of 17-DMAG and belinostat
synergistically inhibited the growth of the H1975 cells
(TKI-resistant) (Fig. 4). The most effective combination
was 250 nM of belinostat with 20 nM of 17-DMAG
(Fig. 4a, b). In the presence of 250 nM of belinostat, IC50
of 17-DMAG was 13 nM (Fig. 4c).
Combination of 17-DMAG and belinostat inhibits
the in vivo growth of tumors derived from TKI-resistant
human NSCLC cells
Immunodeficient mice with xenografts of H1975 cells
(EGFR exons 20 and 21 mutations and TKI-resistant) were
treated with 15 mg/kg of 17-DMAG and/or 50 mg/kg of
belinostat (every other day). Control mice received diluent
alone. 17-DMAG, belinostat and their combination sup-
pressed nearly completely the tumor growth with no sig-
nificant difference in tumor size between each treatment
group (data not shown). All of these mice had no apparent
toxicity. In order to determine whether enhanced suppres-
sion tumor growth occured in the drug combination, we
decreased by 50 % the dose of each compound on day
30 (7.5 mg/kg, 17-DMAG and/or 25 mg/kg, belinostat).
Tumors of the Belinostat-treated mice increased more than
those of the 17-DMAG-treated mice. Combination of
17-DMAG and belinostat was more effective than either
drug alone. Examining for drug toxicities was analyzed on
day 54 for 16 different blood chemistries; no significant
differences occurred between control and experimental
p-Akt
EGF
belinostat
GAPDH
pan-Akt
( µM )
H460 : EGFR wild-type H1650 : TKI-resistance PC9 : TKI-sensitive
p-Akt
EGF
GAPDH
pan-Akt
H460 : EGFR wild-type H1650 : TKI-resistance PC9 : TKI-sensitive
b
17-DMAG
( nM )
a
- + + + +
0 0 0.5 1 2
- + + + +
0 0 0.5 1 2
- + + + +
0 0 0.5 1 2
- + + + +
0 0 50 100 200
- + + + +
0 0 50 100 200
- + + + +
0 0 50 100 200
Fig. 2 Levels of p-Akt in the three subtypes of NSCLC. Cells were
serum-starved (16 h), treated with either belinostat [0, 0.5, 1, 2 lM]
(a) or 17-DMAG [0, 50, 100, 200 nM] (b) for 4 h, stimulated with
EGF (10 ng/ml, 15 min), cell lysate harvested and examined for
levels of p-Akt (Ser473), pan-Akt and GAPDH (loading control) by
Western blotting
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mice (data not shown). Likewise, the mice were weighed
every other day, and no significant difference occurred in
their weights. The mice were euthanized, and tumors were
carefully dissected and weighed (Fig. 5a). Mean tumor
weight of each individual treatment group was significantly
less than that of the control cohort (p \ 0.05, belinostat,
p \ 0.001, 17-DMAG). The mean weight of the tumors in
the combination group was significantly less than that of
either treatment cohort alone (p \ 0.001) (Fig. 5a, b).
17-DMAG and the combination of belinostat and
17-DMAG treatment produced extensive necrosis with
neutrophil infiltration (Fig. 5c). Protein was extracted from
the tumors and Western blotted (Fig. 5d). Levels of
p-EGFR, total EGFR, p-Akt, and p-p70S6K were
decreased by each of the treatments compared to control.
Total p70S6K was only decreased in tumors of mice that
received either 17-DMAG or the combination of
17-DMAG and belinostat (Fig. 5d).
Discussion
A major clinical problem often occurs for patients who
have either an exon 19 or 21 mutation in their EGFR gene.
These patients respond to gefitinib, but after a period of
time, their tumors develop a T790M exon 20 mutation.
These tumors no longer respond to the drug. We show here
that tumors with T790M mutations are inhibited in their
proliferation by belinostat or 17-DMAG. Furthermore, the
combination of both of these compounds synergistically
inhibits growth of these tumors.
The growth inhibitory effects of either belinostat or
17-DMAG were independent of the EGFR mutational
status of the cells (p = 0.2323, p = 0.4455, respectively)
(Supplement Fig. 1B, C); thus, their inhibitory activities
were quite different from gefitinib. Effective cell kill by
gefitinib was highly correlated with the presence of somatic
mutations of EGFR (exons 19 and 21), affecting the kinase
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Fig. 3 Combination of 17-DMAG and belinostat markedly inhibited
cell proliferation of NSCLC. Co-treatment with belinostat (100, 250
and 500 nM) and 17-DMAG (5, 10 and 20 nM) for 72 h inhibited
growth of H1650 cells (TKI-resistant, EGFR exon 19 and PTEN
mutations) greater than either inhibitor alone (a). Calcusyn software
(Biosoft) was used to analyze a data. CI \ 1, CI = 1 and CI [ 1
represent synergism, additive and antagonism of the two compounds,
respectively (b)
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domain of EGFR (p \ 0.0001) (Supplement Fig. 1A). In
contrast, the ‘‘EGFR mutant, TKI-sensitive’’ cohort was
more resistant to cisplatin than was the ‘‘wild-type’’ and the
‘‘EGFR mutant, TKI-resistant’’ cell lines [IC50 average
15.2, 5.0 and 2.83 (lM), respectively] (Supplement
Fig. 1D).
Belinostat treatment decreased the levels of EGFR in all
subtypes of NSCLC (Fig. 1a), resulting in downregulation
of EGFR signaling pathway, thus blunting potential EGFR-
mediated antiapoptotic and pro-survival signals. Belinostat
(500 nM) treatment decreased within 24 h, the constitutive
levels of phospho-Akt in H1650 cells (TKI-resistant, EGFR
exon 19 and PTEN mutations) and PC9 cells (TKI-sensi-
tive, EGFR exon 19 mutation). We previously showed that
a HDAC inhibitor (vorinostat) profoundly decreased the
levels of members of the activated Akt pathway in lym-
phoma cells, associated with their decreased proliferation
[15]. The p-Akt in H460 cells (EGFR wild-type) was not
decreased by belinostat (Fig. 1b). The lack of effect on
constitutively activated p-Akt in these cells may be
explained because H460 cells have a mutation of PI3K and
KRAS [16]. Thus, belinostat may not be able to inhibit the
ability of mutant PI3K and KRAS to activate Akt (Fig. 1b).
The mechanism by which HDAC inhibitors suppress
oncogenic pathways is unclear. One hypothesis is that HDAC
inhibitors activate ‘‘tumor suppressor genes’’ that subse-
quently result in growth inhibition, differentiation and apop-
tosis of cancer cells [17]. We previously combined a HDAC
inhibitor (vorinostat) and a demethylating agent and noted the
initiation of expression of a number of tumor suppressor genes
in a variety of tumors including NSCLC, endometrial, pros-
tate, ovary and pancreatic cancers [15, 18–22]. HDAC
inhibitors also have the ability to regulate a number of key
regulatory processes through acetylation of nonhistone pro-
teins including p53, STAT, FOXO, HIF-1a, E2F1 and pRb
[17, 23]. The HDAC inhibitor, belinostat, most likely sup-
presses several different oncogenic pathways, including the
PI3K-Akt pathway as well as the activated EGFR (Fig. 1a, b).
The Hsp90 chaperone helps mediate the conformational
maturation of several families of hormone receptors, tran-
scription factors and kinases [24]. Inhibition of Hsp90 pre-
vents its association with its client proteins, resulting in the
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Fig. 4 Combination of 17-DMAG and belinostat synergistically
inhibited cell proliferation of TKI-resistant cells. Co-treatment with
belinostat (100, 250 and 500 nM) and 17-DMAG (5, 10 and 20 nM)
for 72 h inhibited growth of H1975 cells (TKI-resistant, EGFR exons
20 and 21 mutations) greater than either inhibitor alone (a). Calcusyn
software (Biosoft) was used to analyze a data. CI \ 1, CI = 1 and
CI [ 1 represent synergism, additive and antagonism of the two
compounds, respectively (b). IC50 at each concentration of combi-
nation of belinostat and 17-DMAG was determined (c)
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conformational change of these target proteins causing an
ubiquitin-mediated proteasomal degradation of the target
proteins [25]. Cancer cells may be particularly dependent on
chaperone proteins to survive a hypoxic, nutrient-starved
microenvironment [26]. In addition, through the process of
‘‘oncogene addiction,’’ cancer cells may be dependent on
either overexpressed or mutant kinases for viability, and hence
making them particularly sensitive to Hsp90 inhibition.
Mutant EGFR can mediate oncogenic addiction, and a Hsp90
inhibitor can prominently lower the levels of this addicting
protein as shown by others [27] and ourselves here. We and
others showed that 17-DMAG decreased the levels of EGFR
in all subtypes of NSCLC, showing that this Hsp90 inhibitor
modulates these receptors independent of the EGFR muta-
tional status (Fig. 1a) [28]. Furthermore, Hsp90 stabilizes the
active (phosphorylated) form of Akt since inhibition of
binding of Akt-Hsp90 resulted in Akt dephosphorylation
causing a loss of Akt kinase activity [24, 25, 29]. We found
that 17-DMAG decreased the levels of activated Akt in all
subtypes of NSCLC (Fig. 1b). Furthermore, when these cells
were serum-starved and stimulated by EGF, 17-DMAG
blunted the activation of p-Akt in H460 cells and PC9 cells
(Fig. 2b). Therefore, the decrease in p-Akt in response to
17-DMAG may be related to both depletion of upstream
EGFR, as well as direct effects on stability and phosphory-
lation of Akt. Early clinical trials have presented a mixed
picture. Use of IPI-504, a water-soluble Hsp90 inhibitor
monotherapy [randomized phase II trial] in advanced
NSCLC, did not show clinical activity [30]. Another Hsp90
inhibitor, [ganetespib (STA-9090)], showed promising dis-
ease control in previously heavily pretreated NSCLC patients
[phase II trial]. This drug appeared to be effective in all subsets
of NSCLC including those with EGFR mutations, ALK
translocations and KRAS mutations [31].
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Fig. 5 Combination of 17-DMAG and belinostat inhibited the in vivo
growth of human TKI-resistant NSCLC xenografts. H1975 cells
[TKI-resistant, EGFR exons 20 (T790M) and 21 mutations] were
injected in the flanks of nude mice (day 1). On alternate days (day
2–30), mice received i.p. injections of either belinostat (50 mg/kg);
17-DMAG (15 mg/kg); combination therapy (belinostat 50 mg/kg
and 17-DMAG 15 mg/kg) or diluent control. After day 30, dose of
drugs was decreased by 50 % [belinostat (25 mg/kg); 17-DMAG
(7.5 mg/kg); and combination therapy (belinostat 25 mg/kg and
17-DMAG 7.5 mg/kg)] and was continued every other day, limited
day 54. Visual display of the dissected tumors from each cohort (a).
Mean ± SD of the weights of the tumors was calculated. Statistical
differences between the cohorts were determined using Bonferroni/
Dunn multiple comparison test (b). Tumor sections were stained with
hematoxylin and eosin, and immunohistochemistry for Ki67 was done
(cell proliferation). Magnification was 9200 (c). Cell lysates were
made from the dissected tumors and examined for levels of p-EGFR,
EGFR, p-Akt, pan-Akt, p-p70S6K and p70S6K and GAPDH (loading
control) by Western blotting (d)
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Combination of 17-DMAG and belinostat resulted in
in vitro enhanced inhibition of proliferation of the TKI-
resistant NSCLC cells (Figs. 3, 4). A previous study showed
that panobinostat caused acetylation of Hsp90, reducing its
association with mutant EGFR, Akt and STAT3, resulting in
ubiquitination and depletion of these growth-promoting
proteins in NSCLC cells [24, 25]. Therefore, our combina-
tion of a HDAC and a Hsp90 inhibitor may lead to a profound
disruption of the chaperone function of Hsp90 with its client
proteins, resulting in increased polyubiquitylation and pro-
teasomal degradation of the client protein. In addition, we
showed that either 17-DMAG or belinostat, or their combi-
nation inhibited TKI-resistant NSCLC xenografts growing
in immunodeficient mice (Fig. 5a). Further, the combination
of both therapies prominently decreased the mean tumor
weight compared to tumor weights of those mice who
received either belinostat or 17-DMAG alone (Fig. 5b).
Similar to our in vitro results, Western blotting of cell lysates
of tumors showed that either belinostat or 17-DMAG
decreased expression of EGFR, p-Akt and its downstream
signaling molecules (Fig. 5c). These mice had no chemical
or physical manifestations of toxicity.
In summary, our data show that belinostat and 17-DMAG
markedly inhibit the proliferation of the TKI-resistant
NSCLC cells associated with decreased levels of both EGFR
and activated Akt (p-Akt). Combination therapy with these
compounds has the potential to be a therapeutic strategy for
patients with EGFR-TKI-resistant NSCLCs.
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